REVMED Wins 2025 Korea Trusted Innovation Award for Technological Excellence

South Korean biomedical company REV-MED Co., Ltd. (CEO Shin Bong-geun) has been honored with the Next-Generation Regenerative Medicine Technology Innovation Award at the 2025 Korea Trusted Innovation Awards, jointly hosted by JoongAng Ilbo and Forbes Korea.

The recognition highlights REV-MED’s efforts to address long-standing challenges in regenerative medicine—namely, inconsistencies in clinical outcomes and the unpredictability of treatment results—through its standardized technology platform.

According to the company, REV-MED enhanced procedural stability in the regenerative medicine field with its patented “Triple-Chamber Biological Separation Kit.”

The technology is designed to prevent external contamination while enabling dual-phase centrifugation, ensuring consistent cell separation efficiency regardless of the practitioner’s skill level.

A REV-MED spokesperson explained that the system “transforms experience-dependent processes into standardized protocols,” paving the way for more predictable and reliable results in clinical settings.

REV-MED has also focused on improving medical staff safety, an issue often overlooked in clinical environments.

Its next-generation platform, NovaStem, adopts a needleless system that eliminates the use of hypodermic needles and employs an international Luer-lock standard to reduce the risk of accidental needle injuries and cross-contamination.

“The safety of healthcare professionals is directly linked to the credibility of regenerative medicine procedures,” a company representative said, adding that “the needleless technology significantly minimizes infection risks.”

In addition, the company reported that its NovaStem BMAC (Bone Marrow) kit showed higher CFU-F (Colony Forming Unit–Fibroblast) levels compared to conventional methods, while the DuoCell SVF (Adipose) kit demonstrated increased expression of VEGF (Vascular Endothelial Growth Factor), underscoring the system’s consistency and efficiency.

Beyond cell separation technology, REV-MED has expanded into non-surgical regenerative therapy solutions by integrating its expertise with energy-based medical devices such as the Hilthera 4.0 high-power laser and ReWave microwave device.

The company is also developing a high-efficiency exosome concentration platform as part of its next-generation pipeline, aimed at strengthening its position in the global regenerative medicine market.

“With this award, our philosophy of delivering predictable recovery and trustworthy outcomes has been recognized,” said CEO Shin Bong-geun.

“REV-MED will continue to set new standards in global regenerative medicine through standardized innovation and technological excellence.”